AstraZeneca AstraZeneca

As a global biopharmaceutical company, AstraZeneca has a key contribution to make through the discovery, development and commercialisation of innovative medicines for important areas of healthcare, including cardiovascular disease, diabetes, cancer and respiratory, inflammatory and autoimmune disease.
AstraZeneca has more than 45 years in Bulgaria and is one of the fastest growing companies in the industry.
AstraZeneca Bulgaria is performing active CSR program with focus on making meaningful difference to patients’ healthcare and quality of life and developing young people`s potential.
For its CSR projects AstraZeneca Bulgaria has been granted a number of prestigious awards as Business Oscar for Best CSR program in Europe at the Stevie International Annual Business Awards, Ruban D`Honneur winner in Employer of the Year category by European Business Awards. Investor in community, Investor in Human capital and Cause-related Marketing awards from BBLF.
Three years the company was acknowledged as Best Employer in Bulgaria from Hewitt Associates and was recognized in Top 5 Best Employers in Central Eastern Europe 2009/2010.


Novartis Novartis

Novartis International AG is Swiss multinational pharmaceutical company sitting in Basel, Switzerland.  Novartis develops its activities in three major divisions operating worldwide: innovative medicines / Novartis Pharmaceuticals / Eye care / Alcon / and generic drugs / Sandoz /. These three divisions are supported by our organization for research and development. In 2014 the company is а worldwide leader with sales income approximately 58 billion dollars. The company invests 17% of these incomes in research and development. Novartis has more than 120 000 employees from 150 nationalities. The company claims to create and develop innovative medications covering unmet medical needs. Annually the medications of Novartis are being used by more than 1.2 billion people all over the world. In Bulgaria the company has more than 100 employees and Novartis is number one in sales in the country for three consecutive years.

Novo Nordisk Novo Nordisk

Novo Nordisk is a Danish global healthcare company with 90 years of innovation and leadership in diabetes care. The company is a leader in insulin production in the world and is the only one manufacturing everything necessary for the modern insulin treatment – insulin, insulin pens and needles. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries, where they reach more than 23 million patients. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

Amgen Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen's medicines treat serious illnesses. We have a presence in more than 75 countries worldwide and have reached millions of people in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. Our medicines typically address diseases for which the number of effective treatment options is limited, or they are medicines that provide a viable option to what is otherwise available.

The National Union of Private Hospitals The National Union of Private Hospitals

The National Union of Private Hospitals (NUPH) is a nongovernment organization of hospitals and their hospital managers, uniting private enterpreneurship to achieve higher quality in the treatment of patients, improving the healthcare system in Bulgaria and promoting effective and efficient mechanisms healthcare management. The National Union of Private Hospitals was established on February 16, 2013 and it now represents almost 70% of the private  hospital sector in the country. Our members of among the most successful, proven and dynamic due to patients' trust hospitals.